By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CardioDx, Inc. 

2500 Faber Place

Palo Alto  California  94303  U.S.A.
Phone: 650-475-2788 Fax: 650-475-2799



Start Up

Company News
CardioDx Release: New Study Published In The American Journal Of Medicine Expands The Clinical Evidence Underscoring The Value Of The Corus CAD Blood Test To Help Safely Direct Cardiovascular Care 4/13/2017 12:24:04 PM
CardioDx Release: PROMISE Substudy Results, Published In The American Heart Journal, Provide Independent Validation Of The Clinical Value Of The Corus(R) CAD Blood Test To Accurately Identify Patients With Obstructive CAD 2/6/2017 8:52:44 AM
CardioDx Announces Final Endpoint Results From The PRESET Registry At The AHA Scientific Sessions 2016 11/15/2016 11:31:36 AM
CardioDx Names Former Siemens (SI) Exec as New CEO 6/1/2016 7:49:19 AM
CardioDx, Inc. Release: PROMISE Trial Substudy Demonstrates That the Corus CAD Blood Test Is Associated With Clinical Events Among Patients Being Evaluated For Suspected Obstructive Coronary Artery Disease 4/5/2016 9:06:06 AM
Timothy Henn, Experienced Genomics Diagnostics And Life Sciences Executive, Joins CardioDx, Inc. As Chief Financial Officer 12/16/2015 11:58:58 AM
CardioDx, Inc. Announces Positive Data From A Large Primary Care Registry On The Impact Of The Corus CAD Test In The Assessment Of Obstructive Coronary Artery Disease In Women 10/2/2015 11:00:07 AM
CardioDx, Inc. Expands Patient Access To The Corus CAD Test Through National Agreement With Quest Diagnostics (DGX) 9/16/2015 11:15:01 AM
CardioDx, Inc. Announces Positive Results From Clinical Utility Study Evaluating The Corus CAD Blood Test's Influence On Clinical Decision-Making In The Assessment Of Obstructive Coronary Artery Disease In Women 4/2/2015 11:51:22 AM
Cardiovascular Disease Diagnostic Company CardioDx, Inc. Withdraws IPO 12/24/2014 6:43:30 AM